Two Huge Catalysts Are About to Reward Pot Stock Investors

Last week, I showed you just how profitable "frontier investing" can be.

It's a deceptively simple, powerful approach I take for my Nova-X Report readers: Research a good investment, build a thesis, target the best stock before Street analysts know it exists, and let the profits come to you as the crowd piles in.

Silicon Valley is a hotbed of this kind of investing; one where my readers have been able to make a killing. Biotech and the life sciences are two others.

Cannabis investing is the latest and most profitable.

It's easier now than it's ever been to get wired into the growth.

And, thanks to what I'm about to show you, there's plenty of that on the way...

The Broadest Exposure to a Booming Sector

As recently as 2013, legally sanctioned "medical marijuana" was worth about $1.5 billion in sales.

But in 2017 - when more than half the states in the Union have some form of legal medical or recreational use laws - the cannabis sector will be worth $6.7 billion... $35 billion by 2020... and $100 billion by 2029.

pot stocksThat represents huge, long-term profit potential for investors on the "frontier" right now.

There's been a new development, though, that, as I said, makes it easy to tap into the upside here.

Even better, it represents a massive leap forward in the credibility of the entire cannabis sector - irresistible bait for the "crowd" who are going to pour in and boost early investor profits.

You see, cannabis just joined the ETF game.

This week marked the historic launch of the Horizons Medical Marijuana Life Sciences ETF (TSE: HMMJ) on the Toronto Stock Exchange.

This first-of-its-kind fund is composed of 14 Canadian and U.S. cannabis stocks.

A marijuana ETF offers a "one-stop shot" for broad sector exposure. What's more, it can limit losses and maximize upside, and, therefore, it offers one safe way to play the $6.7 billion North American cannabis market.

Here's why...

ETFs help protect investors through diversification that offsets losses from single stocks - after all, some marijuana stocks can be volatile.

But there's also plenty of "upside volatility"; I've seen individual weed stocks across the market zoom as much as 1,016%, 630%, 243%, 182%, and 158%.

I'm expecting a fresh round of gains to come in, thanks a revolutionary development up across the "frontier" in Canada.

[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]

The Great White North Is Going Green

The Nova-X Report

Michael's readers are already making a killing on his recommendations in frontier stocks, the best tech shares, and, of course, bioscience companies.

What's more, he makes sure every subscriber gets a copy of his "weed investors'" bible, The Roadmap to Marijuana Millions, with 30 of the best high-profit cannabis plays on the market.

Click here to learn how to get your own copy...

March 27, 2017, is going to go down as a pivotal day for cannabis investors.

In fact, I'm already calling it "Green Monday."

Some leaks out of the capital, Ottawa, revealed some hard details about plans underway to legalize and regulate marijuana not just on one province, but in the entire country.

The bottom line is this: If everything goes according to plan, and the country's parliament and prime minister act as they've said they will, we're looking at full, nationwide medicinal and recreational legalization on July 1, 2018.

Uruguay's legalization aside, this'll mark the first time a fully developed economy has gone for full legalization. Remember, even in the famously weed-friendly Netherlands, use is simply decriminalized or "getolereerd" - tolerated.  

The news sent pot-stock investors into a buying frenzy, sparking huge gains in many of the sector's best stocks.

So, according to my "frontier investing" concept, we're at a critical point. The market is starting to catch up with what you and my Nova-X Report readers have known for about six months: Legal marijuana is all but inevitable, including here in the United States.

All we have to do is wait for the gains. But we don't want to be complacent and sit around while we wait...

New Research Presentation Next Week

Now, it took me a year to research and assemble the Roadmap to Marijuana Millions report, but of course I've never stopped my search for the best weed investments.

I've found five small companies - some of them trade for less than $5 now - that are uniquely positioned to profit when Canada pulls the trigger and takes pot fully legal.

Judging by the "Green Monday" gains, investors who grab these stand to potentially make a fortune - I'm talking the kind of money that turns a tiny stake into $100,000 or more.

I'm presenting my latest research in an online event (think of it as a "Pot Stock Millionaire Summit") on Thursday, April 13, 2017, at 6 p.m. Eastern. Like I said, the market is starting to catch on here, so I'm expecting spots to go fast. Click here and reserve your spot, and you'll get to be among the first to check out my findings.

Follow Michael Robinson on Facebook and Twitter.

About the Author

Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...

  • He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
  • He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
  • As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.

This all means the entire world is constantly seeking Michael's insight.

In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.

Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.

And even with decades of experience, Michael believes there has never been a moment in time quite like this.

Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.

To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.

His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.

Read full bio